Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bolt Biotherapeutics Inc (BOLT)

Bolt Biotherapeutics Inc (BOLT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,403
  • Shares Outstanding, K 1,919
  • Annual Sales, $ 7,690 K
  • Annual Income, $ -63,120 K
  • EBIT $ -44 M
  • EBITDA $ -45 M
  • 60-Month Beta 0.93
  • Price/Sales 1.33
  • Price/Cash Flow N/A
  • Price/Book 0.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -4.27
  • Number of Estimates 3
  • High Estimate -3.82
  • Low Estimate -4.78
  • Prior Year -7.60
  • Growth Rate Est. (year over year) +43.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.41 +22.90%
on 11/17/25
5.45 -0.55%
on 12/04/25
+0.55 (+11.29%)
since 11/05/25
3-Month
4.41 +22.90%
on 11/17/25
6.63 -18.19%
on 10/08/25
+0.23 (+4.43%)
since 09/05/25
52-Week
4.41 +22.90%
on 11/17/25
12.60 -56.98%
on 01/07/25
-5.84 (-51.87%)
since 12/05/24

Most Recent Stories

More News
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026  Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD...

BOLT : 5.42 (+2.07%)
Immunotherapy Breakthroughs Propel Clinical Momentum Ahead of ESMO Congress

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Researchers at Ohio State University just unlocked why many cancer immunotherapies fail, identifying a protein...

KZIA : 15.26 (+1.42%)
CELC : 105.63 (-0.23%)
GRAL : 99.94 (-1.03%)
BOLT : 5.42 (+2.07%)
GTBP : 0.6400 (+5.02%)
KZA.AX : 0.080 (+9.59%)
Bolt Biotherapeutics Announces Major Restructuring Plan

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

BOLT : 5.42 (+2.07%)
Lake Street Keeps Their Buy Rating on Bolt Biotherapeutics (BOLT)

Lake Street analyst Chad Messer maintained a Buy rating on Bolt Biotherapeutics today and set a price target of $75.00. The company’s shares closed yesterday at $5.66.Elevate Your Investing Strategy:...

BOLT : 5.42 (+2.07%)
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026 Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct....

BOLT : 5.42 (+2.07%)
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD...

BOLT : 5.42 (+2.07%)
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

BOLT : 5.42 (+2.07%)
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

BOLT : 5.42 (+2.07%)
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbodyâ„¢ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

BOLT : 5.42 (+2.07%)
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

BOLT : 5.42 (+2.07%)

Business Summary

Bolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company's principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California.

See More

Key Turning Points

3rd Resistance Point 5.88
2nd Resistance Point 5.67
1st Resistance Point 5.54
Last Price 5.42
1st Support Level 5.20
2nd Support Level 4.99
3rd Support Level 4.86

See More

52-Week High 12.60
Fibonacci 61.8% 9.47
Fibonacci 50% 8.50
Fibonacci 38.2% 7.54
Last Price 5.42
52-Week Low 4.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar